Related Experiment Videos
Simvastatin suppresses experimental aortic aneurysm expansion.
Arun Kalyanasundaram1, James R Elmore, James R Manazer
1Section of Vascular Surgery, Weis Center for Research, Geisinger Clinic, Danville, PA 17822-2150, USA.
Journal of Vascular Surgery
|January 18, 2006
Summary
Simvastatin significantly reduced abdominal aortic aneurysm (AAA) expansion in rats by decreasing inflammation and matrix remodeling. This suggests simvastatin may help suppress AAA growth as an adjuvant therapy.
Area of Science:
- Vascular Biology
- Pharmacology
- Biochemistry
Background:
- Abdominal aortic aneurysm (AAA) formation involves inflammation and extracellular matrix (ECM) remodeling.
- Matrix metalloproteinases (MMPs) play a key role in AAA pathogenesis.
- Hydroxymethylglutaryl-coenzyme A inhibitors (statins) possess anti-inflammatory properties.
Purpose of the Study:
- To investigate the efficacy of simvastatin in suppressing experimental AAA formation.
- To determine simvastatin's effects on MMPs and inflammatory mediators in an AAA model.
Main Methods:
- An elastase-induced rat AAA model was utilized.
- Rats received daily simvastatin or placebo treatment.
- Aortic diameter, protein expression (MMP-9, NF-κB), and gene expression were analyzed.
Main Results:
- Simvastatin significantly reduced mean aneurysm diameter compared to placebo (P = .0001).
- Protein levels of MMP-9 and nuclear factor-kappaB were decreased by simvastatin.
- Gene array analysis revealed downregulation of inflammatory, ECM remodeling, and oxidative stress-related genes.
Conclusions:
- Simvastatin effectively suppresses experimental AAA expansion.
- Simvastatin reduces key proteins (MMP-9, NF-κB) involved in AAA pathogenesis.
- Simvastatin's anti-inflammatory effects, via downregulation of proinflammatory genes, suggest its potential as an adjuvant therapy for small AAA.